Gravitate Health FHIR Implementation Guide (FHIR R4)
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide (FHIR R4), published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health-ips/ and changes regularly. See the Directory of published versions

## Example Bundle: IPS Example 3

id: gravitate-ips-3
Composition status: final
Composition Type: Patient summary Document
Subject:
identifier: ips-3
Name: IPS 3 example Gravitate
active: true
gender: female
Birth Date: 1978-05-05

### Sections

#### Allergies and Intolerances

Allergy: Pollen (256259004)
clinicalStatus: active
verificationStatus: confirmed
Reaction: Allergic rhinitis caused by pollen (21719001)

#### Problem List

Condition: Psoriasis (9014002)
clinicalStatus: active
asserter: Dr. Anna Karlsson
Condition: Congestive heart failure (42343007)
clinicalStatus: active
asserter: Dr. Anna Karlsson
onsetDateTime: 2015
Condition: Hypertension (38341003)
clinicalStatus: active
onsetDateTime: 1993

#### Medication Summary

Medication: Dimethyl fumarate 30 mg Tablet
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: EU/1/17/1201/001 [Skilarence]

- System https://www.who-umc.org/phpid Code: 0x9982CA8A825D4561506CE808982E3B9D [dimethyl fumarate, 30 mg/ 1 tablet, Gastro-resistant tablet]

- System http://www.whocc.no/atc Code: L04AX07 [dimethyl fumarate]

Dose Form: Gastro-resistant tablet
Ingredient: dimethyl fumarate (http://fdasis.nlm.nih.gov#FO2303MNI2)
strength: 30 mg/1 Tablet
Route: Oral use
Medication: Irbesartan 75 mg Tablet
status: active
Medication Detail:

- System https://spor.ema.europa.eu/pmswi Code: EMEA/H/C/000142 [Karvea]

- System https://www.who-umc.org/phpid Code: 0x8DFB446EDB3B8AE508AE493827A704E4 [Irbesartan, 75 mg/ 1 tablet, Tablet]

- System http://www.whocc.no/atc Code: C09DA04 [irbesartan and diuretics]

Dose Form: Tablet
Ingredient: irbesartan (http://fdasis.nlm.nih.gov#J0E2756Z7N)
strength: 75 mg/1 Tablet
Route: Oral use
Medication: Oxymetazoline hydrochloride 0.05 mg / 1 ml Spray
status: active
Medication Detail:

- System https://www.gravitatehealth.eu/sid/man Code: 16028/0049 [Boots Decongestant 0.05% w/v Nasal spray]

- System https://www.who-umc.org/phpid Code: 0xF79CABF272B6A7EEF104DDDA44E82716 [Oxymetazoline hydrochloride, 0.5 mg/ 1 ml, Nasal spray, solution]

- System http://www.whocc.no/atc Code: R01AA05 [oxymetazoline]

Dose Form:
Ingredient: oxymetazoline hydrochloride (http://fdasis.nlm.nih.gov#K89MJ0S5VY)
strength: 0.05 mg/1 ml
Route: Nasal use

#### Pregnancy History